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HIGH ACTIVITY MUTANTS OF 
BUTYRYLCHOLINESTERASE FOR 
COCAINE HYDROLYSIS 
RELATED APPLICATIONS 
This application is a division of and claims bene?t to US. 
patent application Ser. No. 12/767,128, noW allowed, ?led 
Apr. 26, 2010, now US. Pat. No. 7,892,537, Which is a 
divisional of US. patent application Ser. No. 12/685,341, 
?led Jan. 11, 2010, noW issued as US. Pat. No. 7,740,840, 
Which is a continuation-in-part of US. patent application Ser. 
No. 12/192,394 ?led Aug. 15, 2008, noW issued as US. Pat. 
No. 7,731,957, Which is a divisional of US. patent applica 
tion Ser. No. 11/243,111, ?led Oct. 4, 2005, noW issued as 
US. Pat. No. 7,438,904. The entire disclosures contained in 
US. patent application Ser. No. 12/767,128, US. Pat. No. 
7,740,840, US. Pat. No. 7,731,957, US. Pat. No. 7,438,904 
are incorporated herein by this reference. 
GOVERNMENT INTEREST 
Subject matter described herein Was made With govem 
ment support under Grant Number R01DA013930 aWarded 
by the National Institute on Drug Abuse (NIDA) of the 
National Institutes of Health (NIH). The government has 
certain rights in the described subject matter. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to butyryl 
cholinesterase variant polypeptides, and in particular, 
butyrylcholinesterase mutants having amino acid substitu 
tions. 
INTRODUCTION 
Cocaine abuse is a major medical and public health prob 
lem that continues to defy treatment. The disastrous medical 
and social consequences of cocaine addiction, such as violent 
crime, loss in individual productivity, illness, and death, have 
made the development of an effective pharmacological treat 
ment a high priority. HoWever, cocaine mediates its reinforc 
ing and toxic effects by blocking neurotransmitter reuptake 
and the classical pharmacodynamic approach has failed to 
yield small-molecule receptor antagonists due to the di?icul 
ties inherent in blocking a blocker. An alternative to receptor 
based approaches is to interfere With the delivery of cocaine 
to its receptors and accelerate its metabolism in the body. 
The dominant pathWay for cocaine metabolism in primates 
is butyrylcholinesterase (BChE)-catalyZed hydrolysis at the 
benZoyl ester group (Scheme 1). 
Scheme 1. Schematic representation of BChE-catalyzed 
hydrolysis at the benzoyl ester group. 
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Only 5% of the cocaine is deactivated through oxidation by 
the liver microsomal cytochrome P450 system. Cocaine 
hydrolysis at benZoyl ester group yields ecgonine methyl 
ester, Whereas the oxidation produces norcocaine. The 
metabolite ecgonine methyl ester is a biologically inactive 
metabolite, Whereas the metabolite norcocaine is hepatotoxic 
and a local anesthetic. BChE is synthesiZed in the liver and 
Widely distributed in the body, including plasma, brain, and 
lung. Extensive experimental studies in animals and humans 
demonstrate that enhancement of BChE activity by adminis 
tration of exogenous enZyme substantially decreases cocaine 
half-life. 
Enhancement of cocaine metabolism by administration of 
BChE has been recogniZed to be a promising pharmacoki 
netic approach for treatment of cocaine abuse and depen 
dence. HoWever, the catalytic activity of this plasma enZyme 
is three orders-of-magnitude loWer against the naturally 
occurring (—)-cocaine than that against the biologically inac 
tive (+)-cocaine enantiomer. (+)-cocaine can be cleared from 
plasma in seconds and prior to partitioning into the central 
nervous system (CNS), Whereas (—)-cocaine has a plasma 
half-life of approximately 45-90 minutes (for a relatively loW 
dose of cocaine), long enough for manifestation of the CNS 
effects Which peak in minutes. Under the overdose condition, 
BChE is saturated With (—)-cocaine and, thus, the plasma 
half-life of (—)-cocaine Will be longer. Hence, BChE mutants 
With high activity against (—)-cocaine are highly desired for 
use in humans. Although some BChE mutants With increased 
catalytic activity over Wild-type BChE have previously been 
generated, there exists a need for mutant BChE With even 
higher catalytic activity. 
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SUMMARY 
The presently-disclosed subject matter meets some or all of 
the above-identi?ed needs, as Will become evident to those of 
ordinary skill in the art after a study of information provided 
in this document. 
This Summary describes several embodiments of the pres 
ently-disclosed subject matter, and in many cases lists varia 
tions and permutations of these embodiments. This Summary 
is merely exemplary of the numerous and varied embodi 
ments. Mention of one or more representative features of a 
given embodiment is likeWise exemplary. Such an embodi 
ment can typically exist With or Without the feature(s) men 
tioned; likewise, those features can be applied to other 
embodiments of the presently-disclosed subject matter, 
Whether listed in this Summary or not. To avoid excessive 
repetition, this Summary does not list or suggest all possible 
combinations of such features. 
The presently-disclosed subject matter includes butyryl 
cholinesterase (BChE) polypeptide variants. In some 
embodiments the amino acid sequence of the BChE polypep 
tide variant includes an amino acid sequence selected from 
the group consisting of: SEQ ID NOS: 2, 4, 6, 8, l0, l2, l4, 
l6, 18, 20, 22, 24, 26, 28, 30, and 32, as set forth herein. 
The presently-disclosed subject matter further includes a 
pharmaceutical composition that includes a butyrylcholinest 
erase polypeptide variant and a suitable pharmaceutical car 
rier. 
The presently-disclosed subject matter further includes a 
method of treating a cocaine-induced condition, Which 
includes administering to an individual an effective amount of 
BChE polypeptide variant or a pharmaceutical composition 
comprising a BChE polypeptide variant, as described herein, 
to loWer blood cocaine concentration. In some embodiments, 
the BChE polypeptide variant exhibits a one-hundred-fold or 
more increase in cocaine hydrolysis catalytic e?iciency com 
pared to Wild-type butyrylcholinesterase. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: 1 is a nucleotide sequence encoding a butyryl 
cholinesterase (BChE) polypeptide variant of SEQ ID NO: 2; 
SEQ ID NO: 2 is an amino acid sequence encoding a BChE 
polypeptide variant having the folloWing amino acid substi 
tutions, as compared to Wild type BChE: Al 99S, F227A, 
P285A, S287G, A328W, andY332G; 
SEQ ID NO: 3 is a nucleotide sequence encoding a butyryl 
cholinesterase (BChE) polypeptide variant of SEQ ID NO: 4; 
SEQ ID NO: 4 is an amino acid sequence encoding a BChE 
polypeptide variant having the folloWing amino acid substi 
tutions, as compared to Wild type BChE: Al 99S, F227A, 
P285S, S287G, A328W, and Y332G; 
SEQ ID NO: 5 is a nucleotide sequence encoding a butyryl 
cholinesterase (BChE) polypeptide variant of SEQ ID NO: 6; 
SEQ ID NO: 6 is an amino acid sequence encoding a BChE 
polypeptide variant having the folloWing amino acid substi 
tutions, as compared to Wild type BChE: Al 99S, F227A, 
P285Q, S287G, A328W, andY332G; 
SEQ ID NO: 7 is a nucleotide sequence encoding a butyryl 
cholinesterase (BChE) polypeptide variant of SEQ ID NO: 8; 
SEQ ID NO: 8 is an amino acid sequence encoding a BChE 
polypeptide variant having the folloWing amino acid substi 
tutions, as compared to Wild type BChE: Al 99S, F227P, 
S287G, A328W, and Y332G. 
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SEQ ID NO: 9 is a nucleotide sequence encoding a butyryl 
cholinesterase (BChE) polypeptide variant of SEQ ID NO: 
10; 
SEQ ID NO: 10 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: Al99S, 
F227A, P285G, S287G, A328W, andY332G; 
SEQ ID NO: 11 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 12; 
SEQ ID NO: 12 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: Al99S, 
F227A, L286M, S287G, A328W, andY332G; 
SEQ ID NO: 13 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 14; 
SEQ ID NO: 14 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: Al99S, 
P285Q, S287G, A328W, andY332G; 
SEQ ID NO: 15 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 16; 
SEQ ID NO: 16 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wildtype BChE: Al 99S, P285I, 
S287G, A328W, andY332G; 
SEQ ID NO: 17 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 18; 
SEQ ID NO: 18 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: Al99S, 
F227G, S287G, A328W, andY332G; 
SEQ ID NO: 19 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 20; 
SEQ ID NO: 20 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: Al99S, 
P285S, S287G, A328W, andY332G; 
SEQ ID NO: 21 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 22; 
SEQ ID NO: 22 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: Al99S, 
F227V, S287G, A328W, andY332G; 
SEQ ID NO: 23 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 24; 
SEQ ID NO: 24 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: Al99S, 
P285G, S287G, A328W, andY332G; 
SEQ ID NO: 25 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 26; 
SEQ ID NO: 26 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: Al99S, 
F2271, S287G, A328W, andY332G; 
SEQ ID NO: 27 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 28; 
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SEQ ID NO: 28 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to Wild type BChE: A199S, 
F227L, S287G, A328W, andY332G; 
SEQ ID NO: 29 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 30; 
SEQ ID NO: 30 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: A199S, 
L286M, S287G, A328W, andY332G; 
SEQ ID NO: 31 is a nucleotide sequence encoding a 
butyrylcholinesterase (BChE) polypeptide variant of SEQ ID 
NO: 32; and 
10 
6 
cholinesterase polypeptide variant, as described herein, and a 
suitable pharmaceutical carrier. The presently-disclosed sub 
ject matter further includes a method of treating a cocaine 
induced condition comprising administering to an individual 
an effective amount of a butyrylcholinesterase polypeptide 
variant, as disclosed herein, to loWer blood cocaine concen 
tration. 
In some embodiments, the BChE polypeptide variant is 
selected from a BChE polypeptide variants set forth in Table 
1. Table 1 also includes the SEQ ID NOs associated With the 
identi?ed BChE polypeptide variants, as Well as a summary 
of the approximate fold increase in catalytic ef?ciency 
against (—)-cocaine for the identi?ed BChE polypeptide vari 
ants, as compared to Wild type BChE. 
TABLE 1 
BChE Polypeptide Variants and Associated SEQ ID NOs 
Catalytic 
Ef?ciency 
(km/KM) 
against Nucleic Amino 
(—)—cocaine Acid Acid 
(Approx- SEQ SEQ 
Variant Amino Acid Substitution imate Fold ID ID 
Number 199 227 285 286 287 328 332 Increase)” NO: NO: 
1 A199S F227A P285A i S287G A328W Y332G 4080 1 2 
2 A199S F227A P285S i S287G A328W Y332G 3700 3 4 
3 A199S F227A P285Q i S287G A328W Y332G 3590 5 6 
4 A199S F227P i i S287G A328W Y332G 1860 7 8 
5 A199S F227A P285G i S287G A328W Y332G 2420 9 10 
6 A199S F227A i L286M S287G A328W Y332G 2120 11 12 
7 A199S * P285Q * S287G A328W Y332G 2220 13 14 
8 A199S i P2851 i S287G A328W Y332G 830 15 16 
9 A199S F227G i i S287G A328W Y332G 2010 17 18 
10 A199S i P285S i S287G A328W Y332G 1240 19 20 
11 A199S F227V i i S287G A328W Y332G 950 21 22 
12 A199S i P285G i S287G A328W Y332G 1250 23 24 
13 A199S F2271 i i S287G A328W Y332G 1240 25 26 
14 A199S F227L i i S287G A328W Y332G 1100 27 28 
15 A199S i i L286M S287G A328W Y332G 740 29 30 
16 A199S F227A P285K i S287G A328W Y332G 1540 31 32 
“The approximate ratio ofthe kCa/KM value for the BChE mutant to that for the Wild-type BChE against (—)-cocaine. 
SEQ ID NO: 32 is an amino acid sequence encoding a 
BChE polypeptide variant having the folloWing amino acid 
substitutions, as compared to Wild type BChE: A199S, 
F227A, P285K, S287G, A328W, andY332G. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently 
disclosed subject matter are set forth in this document. Modi 
?cations to embodiments described in this document, and 
other embodiments, Will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the speci?c details of the described exemplary 
embodiments, is provided primarily for cleamess of under 
standing and no unnecessary limitations are to be understood 
therefrom. In case of con?ict, the speci?cation of this docu 
ment, including de?nitions, Will control. 
The presently-disclosed subject matter includes butyryl 
cholinesterase (BChE) polypeptide variants. The BChE 
polypeptide variants disclosed herein each have enhanced 
catalytic ef?ciency for (—)-cocaine, as compared to Wild-type 
BChE. The presently-disclosed subject matter further 
includes a pharmaceutical composition including a butyryl 
45 
50 
55 
60 
65 
The terms “polypeptide , protein”, and “peptide”, Which 
are used interchangeably herein, refer to a polymer of the 
protein amino acids, or amino acid analogs, regardless of its 
siZe or function. Although “protein” is often used in reference 
to relatively large polypeptides, and “peptide” is often used in 
reference to small polypeptides, usage of these terms in the art 
overlaps and varies. The term “polypeptide” as used herein 
refers to peptides, polypeptides, and proteins, unless other 
Wise noted. The terms “protein”, “polypeptide”, and “pep 
tide” are used interchangeably herein When referring to a gene 
product. Thus, exemplary polypeptides include gene prod 
ucts, naturally occurring proteins, homologs, orthologs, para 
logs, fragments and other equivalents, variants, and analogs 
of the foregoing. 
The term “variant” refers to an amino acid sequence that is 
different from the reference polypeptide by one or more 
amino acids, e.g., one or more amino acid substitutions. For 
example a butyrylcholinesterase (BChE) polypeptide variant 
differs from Wild-type BChE by one or more amino acid 
substitutions, i.e., mutations. 
The terms “polypeptide fragment” or “fragment”, When 
used in reference to a reference polypeptide, refers to a 
polypeptide in Which amino acid residues are deleted as com 
pared to the reference polypeptide itself, but Where the 
remaining amino acid sequence is usually identical to the 
US 8,206,703 B1 
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corresponding positions in the reference polypeptide. Such 
deletions can occur at the amino-terminus, carboxy-terminus 
of the reference polypeptide, or alternatively both. A frag 
ment can also be a “functional fragment,” in Which case the 
fragment retains some or all of the activity of the reference 
polypeptide as described herein. For example, a functional 
fragment of a particular BChE polypeptide variant retains 
some or all of the cocaine hydrolysis activity, i.e., the catalytic 
ef?ciency for (—)-cocaine, of the particular BChE polypep 
tide variant. In this regard, the term “BChE polypeptide vari 
ant” is inclusive of functional fragments of the BChE 
polypeptide variant. Such fragments are typically are at least 
about300, 325, 350, 375, 400, 425, 450, 475, 500, 525, or 550 
amino acids long. One or more residues from about 1 to 67 
and/or one or more residues from about 443 to 574 can be 
removed Without substantially affecting the catalytic activity 
of the BChE polypeptide variant. As such, the term “BChE 
polypeptide variant” is inclusive of functional fragments 
Wherein one or more residues from 1 to 67 and/ or one or more 
residues from 443 to 574 is truncated relative to the full 
length BChE polypeptide variant. 
The BChE polypeptide variant (e.g., SEQ ID NOS: 2, 4, 6, 
8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32) can be 
formulated in a pharmaceutical composition along With a 
suitable pharmaceutical carrier knoWn to one skilled in the 
art. 
The present BChE variant polypeptides can be used in 
treating a cocaine-induced condition by administering to an 
individual, an effective amount of a BChE variant polypep 
tides, (e.g., SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 
24, 26, 28, 30, and 32), to loWer blood cocaine concentration. 
The BChE polypeptide variant can be administered in the 
form of a pharmaceutical composition in Which the BChE 
polypeptide variant is included With a suitable pharmaceuti 
cal carrier. Treatment of a cocaine-induced condition using 
one of the aforementioned BChE polypeptide variants can be 
in a manner that Will be understood by those skilled in the art. 
The preferred dose for administration of a BChE polypep 
tide variant or pharmaceutical composition in accordance 
With the presently-described subject matter is that amount 
Which Will be effective in loWering (—)-cocaine concentration 
in a patient’s bloodstream, and one Would readily recogniZe 
that this amount Will vary greatly depending on the nature of 
cocaine consumed, e. g., injected or inhaled, and the condition 
of a patient. An “effective amount” of butyrylcholinesterase 
polypeptide variant or pharmaceutical composition to be used 
in accordance With the presently-disclosed subject matter is 
intended to mean a nontoxic but su?icient amount of the 
agent, such that the desired prophylactic or therapeutic effect 
is produced. Thus, the exact amount of the enzyme or a 
particular agent that is required Will vary from subject to 
subject, depending on the species, age, and general condition 
of the subject, the severity of the condition being treated, the 
particular carrier or adjuvant being used and its mode of 
administration, and the like. Similarly, the dosing regimen 
should also be adjusted to suit the individual to Whom the 
composition is administered and Will once again vary With 
age, Weight, metabolism, etc. of the individual. Accordingly, 
the “effective amount” of any particular butyrylcholinest 
erase polypeptide variant, or pharmaceutical composition 
thereof, Will vary based on the particular circumstances, and 
an appropriate effective amount may be determined in each 
case of application by one of ordinary skill in the art using 
only routine experimentation. 
The presently-disclosed subject matter is further illustrated 
by the folloWing speci?c but non-limiting examples. The 
folloWing examples may include compilations of data that are 
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representative of data gathered at various times during the 
course of development and experimentation related to the 
presently-disclosed subject matter. 
EXAMPLES 
Embodiments of the BChE polypeptide variants of the 
presently-disclosed subject matter Were made and studied 
using the folloWing experimental procedure. 
Site-directed mutagenesis of human BChE cDNA Was per 
formed by the QuikChange method of Braman, J .; PapWorth, 
C.; Greener, A. Methods Mol. Biol. 1996, 57, 5731, incorpo 
rated herein by this reference. Mutations Were generated from 
Wild-type human BChE in a pRc/CMV expression plasmid in 
accordance With Xie, W.; Altamirano, C. V.; Bartels, C. F.; 
Speirs, R. 1.; Cashman, J. R.; Lockridge, O. Mol. Pharmacol. 
1999, 55, 83, each of Which is incorporated herein by this 
reference. The expression plasmid pRc/CMV Was kindly pro 
vided by Dr. O. Lockridge, University of Nebraska Medical 
Center (Omaha, Nebr.). 
Using plasmid DNA as template and primers With speci?c 
base-pair alterations, mutations Were made by polymerase 
chain reaction With Pfu DNA polymerase, for replication 
?delity. The PCR product Was treated With Dpn I endonu 
clease to digest the parental DNA template. Cloned pfu DNA 
polymerase and Dpn I endonuclease Were obtained from 
Stratagene (La Jolla, Calif.). Modi?ed plasmid DNA Was 
transformed into Escherichia coli, ampli?ed, and puri?ed. 
The DNA sequences of the mutants Were con?rmed by DNA 
sequencing. All oligonucleotides Were synthesiZed by the 
Integrated DNA Technologies, Inc. The QIAprep Spin Plas 
mid Miniprep Kit and Qiagen plasmid puri?cation kit and 
QIAquick PCR puri?cation kit Were obtained from Qiagen 
(Santa Clarita, Calif.). 
BChE mutants Were expressed in human embryonic kid 
ney cell line 293T/ 17. Cells Were groWn to 80-90% con?u 
ence in 6-Well dishes and then transfected by Lipofectamine 
2000 complexes of 4 pg plasmid DNA per each Well. Cells 
Were incubated at 370 C. in a CO2 incubator for 24 hours and 
cells Were moved to 60-mm culture vessel and cultured for 
four more days. The culture medium [10% fetal bovine serum 
in Dulbecco’s modi?ed Eagle’s medium (DMEM)] Was har 
vested for a BChE activity assay. 
Human embryonic kidney 293T/ 17 cells Were from ATCC 
(Manassas, Va.). Dulbecco’s modi?ed Eagle’s medium 
(DMEM) Was purchased from Fisher Scienti?c (FairlaWn, 
N.J.). Oligonucleotide primers Were synthesiZed by the Inte 
grated DNA Technologies and Analysis Facility of the Uni 
versity of Kentucky. 3,3',5,5'-TetramethylbenZidine (TMB) 
Was obtained from Sigma (Saint Louis, Mo.). Anti-butyryl 
cholinesterase (mouse monoclonal antibody, Product # 
HAH002-01) Was purchased from AntibodyShop (Gentofte, 
Denmark) and Goat anti-mouse IgG HRP conjugate from 
Zymed (San Francisco, Calif.). 
To measure cocaine and benZoic acid, the product of 
cocaine hydrolysis by BChE, sensitive radiometric assays 
based on toluene extraction of [3H] -(—)-cocaine labeled on its 
benZene ring Were used in accordance With Zheng, F.; Yang, 
W.; Ko, M.-C.; Liu, J.; Cho, H.; Gao, D.; Tong, M.;Tai, H.-H.; 
Woods, J. H.; Zhan, C.-G. “Most Ef?cient Cocaine Hydrolase 
Designed by Virtual Screening of Transition States”, J. Am. 
Chem. Soc. 2008, 130, 12148-12155, Which is incorporated 
herein by this reference. 3H-(—)-cocaine (50 Ci/mmol) Was 
purchased from PerkinElmer Life Sciences (gBoston, Mass.). 
In brief, to initiate reactions, 100 nCi of [ H]-(—)-cocaine 
Was mixed With 100 pl of culture medium. Reactions pro 
ceeded at room temperature (250 C.) With varying concentra 
tions of (—)-cocaine. Reactions Were stopped by adding 300 pl 
of 0.02 M HCl, Which neutraliZed the liberated benZoic acid 
US 8,206,703 B1 
While ensuring a positive charge on the residual cocaine. 
[3H]benZoic acid Was extracted by 1 ml of toluene and mea 
sured by scintillation counting. Finally, the measured (—) 
cocaine concentration-dependent radiometric data Were ana 
lyZed by using the standard Michaelis-Menten kinetics so that 
the catalytic ef?ciency (km/KM) Was determined, along With 
the use of an enZyme-linked immunosorbent assay (ELISA) 
described in by Zheng, F.; Yang, W.; Ko, M.-C.; Liu, 1.; Cho, 
H.; Gao, D.; Tong, M.; Tai, H.-H.; Woods, J. H.; Zhan, C.-G. 
“Most Ef?cient Cocaine Hydrolase Designed by Vrrtual 
Screening of Transition States”, J. Am. Chem. Soc. 2008, 130, 
12148-12155. 
The catalytic ef?ciency (km/KM) of the BChE polypeptide 
variants of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 
24, 26, 28, 30, and 32 are set forth in Table 2. 
TABLE 2 
Catal ic Ei?cienc k K ofBChE Pol e tideVariants 
Catalytic Ef?ciency 
Catalytic Ef?ciency against (—)—cocaine 
Variant Amino Acid against (—)—cocaine (Approximate 
Number SEQ ID NO: (M7l min’l ) Fold Increase)” 
1 2 3.72 X 109 4080 
2 4 3.37 X 109 3700 
3 6 3.27 X 109 3590 
4 s 1.69 X 109 1860 
5 10 2.20 X 109 2420 
6 12 1.93><10g 2120 
7 14 2.02 X 109 2220 
s 16 7.56 X 108 830 
9 1s 1.83><10g 2010 
10 20 1.13><109 1240 
11 22 8.65 ><108 950 
12 24 1.14><10g 1250 
13 26 1.13><109 1240 
14 2s 1.00><109 1100 
15 30 6.74 X 108 740 
16 32 1.40><10g 1540 
“The approximate ratio of the kHz/KM value for the BChE mutant to that for the Wild-type 
BChE against (—)-cocaine. 
The catalytic ef?ciencies (km/KM) of the BChE polypep 
tide variants Were found to be betWeen about 6.74><108 and 
3.72><109 M'l min_l, Which is about 740 to about 4080 times 
the kcat/KM value (9.11><105 M-l min_l) of the Wild-type 
BChE. 
Enzyme-linked immunosorbent assays (ELISA) Were pre 
formed as folloWs. The ELISA buffers used Were the same as 
those described in the literature such as Brock, A.; Mortensen, 
V.; Loft,A. G. R.; Nergaard-Pedersen, B.J. Clin. Chem. Clin. 
Biochem. 1990, 28, 221 -224; and Khattab, A. D.; Walker, C. 
H.; Johnston, G.; Siddiqui, M. K. Saphier, P. W. Environmen 
Zal Toxicology and Chemistry 1994, 13, 1661-1667, both of 
Which are incorporated herein by this reference. The coating 
buffer Was 0.1 M sodium carbonate/bicarbonate buffer, pH 
9.5. The diluent buffer (EIA buffer) Was potassium phosphate 
monobasic/potassium phosphate monohydrate buffer, pH 
7.5, containing 0.9% sodium chloride and 0.1% bovine serum 
albumin. The Washing buffer (PBS-T) Was 0.01 M potassium 
25 
30 
35 
40 
45 
50 
1 0 
phosphate monobasic/potassium phosphate monohydrate 
buffer, pH 7.5, containing 0.05% (v/v) Tween-20. All the 
assays Were performed in triplicate. Each Well of an ELISA 
microtiter plate Was ?lled With 100 11.1 of the mixture buffer 
consisting of 20 11.1 culture medium and 80 11.1 coating buffer. 
The plate Was covered and incubated overnight at 40 C. to 
alloW the antigen to bind to the plate. The solutions Were then 
removed and the Wells Were Washed four times With PBS-T. 
The Washed Wells Were ?lled With 200 11.1 diluent buffer and 
kept shaking for 1.5 h at room temperature (250 C.). After 
Washing With PBS-T for four times, the Wells Were ?lled With 
100 11.1 antibody (1:8000) and Were incubated for 1.5 h, fol 
loWed by Washing for four times. Then, the Wells Were ?lled 
With 100 11.1 goat anti-mouse IgG HRP conjugate complex 
diluted to a ?nal 1:3000 dilution, and Were incubated at room 
temperature for 1.5 h, folloWed by Washing for four times. 
The enZyme reactions Were started by addition of 100 11.1 
substrate (TMB) solution. The reactions Were stopped after 
15 min by the addition of 100 11.1 of 2 M sulfuric acid, and the 
absorbance Was read at 460 nm using a Bio-Rad ELISA plate 
reader. 
While the terms used herein are believed to be Well under 
stood by one of ordinary skill in the art, the de?nitions set 
forth herein are provided to facilitate explanation of the pres 
ently-disclosed subject matter. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to Which the presently 
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently 
disclosed subject matter, representative methods, devices, 
and materials are noW described. 
Following long-standing patent laW convention, the terms 
“a”, “an”, and “the” refer to “one or more” When used in this 
application, including the claims. Thus, for example, refer 
ence to “a cell” includes a plurality of such cells, and so forth. 
Unless otherWise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the speci?cation and claims are to be 
understood as being modi?ed in all instances by the term 
“about”. Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this speci?cation and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
subject matter. 
As used herein, the term “about,” When referring to a value 
or to an amount of mass, Weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments 150%, in some embodiments 140%, in some 
embodiments 130%, in some embodiments 120%, in some 
embodiments 110%, in some embodiments 15%, in some 
embodiments 11%, in some embodiments 10.5%, and in 
some embodiments 10.1% from the speci?ed amount, as such 
variations are appropriate to perform the disclosed method. 
Throughout this document, various references are men 
tioned. All such references are incorporated herein by refer 
ence. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 32 
<2lO> SEQ ID NO 1 
<2ll> LENGTH: 1722 
<2l2> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
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12 
<220> FEATURE: 
<223> OTHER INFORMATION: mutant of human BChE 
<400> SEQUENCE: 1 
gaagatgaca tcataattgc aacaaagaat ggaaaagtca gagggatgaa cttgacagtt 
tttggtggca cggtaacagc ctttcttgga attccctatg cacagccacc tcttggtaga 
cttcgattca aaaagccaca gtctctgacc aagtggtctg atatttggaa tgccacaaaa 
tatgcaaatt cttgctgtca gaacatagat caaagttttc caggcttcca tggatcagag 
atgtggaacc caaacactga cctcagtgaa gactgtttat atctaaatgt atggattcca 
gcacctaaac caaaaaatgc cactgtattg atatggattt atggtggtgg ttttcaaact 
ggaacatcat ctttacatgt ttatgatggc aagtttctgg ctcgggttga aagagttatt 
gtagtgtcaa tgaactatag ggtgggtgcc ctaggattct tagctttgcc aggaaatcct 
gaggctccag ggaacatggg tttatttgat caacagttgg ctcttcagtg ggttcaaaaa 
aatatagcag cctttggtgg aaatcctaaa agtgtaactc tctttggaga aagttccgga 
gcagcttcag ttagcctgca tttgctttct cctggaagcc attcattgtt caccagagcc 
attctgcaaa gtggttccgc taatgctcct tgggcggtaa catctcttta tgaagctagg 
aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 
ccctatggga ctgctttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact 
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 
<210> SEQ ID NO 2 
<211> LENGTH: 574 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: mutant of human BChE 
<400> SEQUENCE: 2 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
20 25 30 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
1200 
1260 
1320 
1380 
1440 
1500 
1560 
1620 
1680 
1722 
13 
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14 
Leu 
Cys 
65 
Met 
Val 
Ile 
Asp 
Asn 
145 
Glu 
Trp 
Thr 
Leu 
Gly 
225 
Asn 
Glu 
Leu 
Ile 
305 
Val 
Phe 
Gly 
Ile 
Tyr 
385 
Pro 
Phe 
Trp 
Pro 
Thr 
50 
Cys 
Trp 
Trp 
Tyr 
Gly 
130 
Tyr 
Ala 
Val 
Leu 
Ser 
210 
Ser 
Arg 
Thr 
Leu 
Phe 
290 
Leu 
Asn 
Ser 
Leu 
Leu 
370 
Arg 
Ala 
Phe 
Met 
Leu 
450 
35 
Lys 
Gln 
Asn 
Ile 
Gly 
115 
Lys 
Arg 
Pro 
Gln 
Phe 
195 
Pro 
Ala 
Thr 
Glu 
Asn 
275 
Gly 
Leu 
Lys 
Lys 
Lys 
355 
Phe 
Glu 
Leu 
Tyr 
Gly 
435 
Glu 
Trp 
Asn 
Pro 
Pro 
100 
Gly 
Phe 
Val 
Gly 
Lys 
180 
Gly 
Gly 
Asn 
Leu 
Ile 
260 
Glu 
Pro 
Glu 
Asp 
Asp 
340 
Ile 
His 
Ala 
Glu 
Tyr 
420 
Val 
Arg 
Ser 
Ile 
Asn 
85 
Ala 
Gly 
Leu 
Gly 
Asn 
165 
Asn 
Glu 
Ser 
Ala 
Asn 
245 
Ile 
Ala 
Thr 
Leu 
Glu 
325 
Asn 
Phe 
Tyr 
Leu 
Phe 
405 
Phe 
Met 
Arg 
Asp 
Asp 
Thr 
Pro 
Phe 
Ala 
Ala 
150 
Met 
Ile 
Ser 
His 
Pro 
230 
Leu 
Lys 
Phe 
Val 
Gly 
310 
Gly 
Asn 
Phe 
Thr 
Gly 
390 
Thr 
Glu 
His 
Asp 
Ile 
55 
Gln 
Asp 
Lys 
Gln 
Arg 
135 
Leu 
Gly 
Ala 
Ser 
Ser 
215 
Trp 
Ala 
Cys 
Val 
Asp 
295 
Gln 
Thr 
Ser 
Pro 
Asp 
375 
Asp 
Lys 
His 
Gly 
Asn 
455 
40 
Trp 
Ser 
Leu 
Pro 
Thr 
120 
Val 
Gly 
Leu 
Ala 
Gly 
200 
Leu 
Ala 
Lys 
Leu 
Val 
280 
Gly 
Phe 
Trp 
Ile 
Gly 
360 
Trp 
Val 
Lys 
Arg 
Tyr 
440 
Tyr 
Asn 
Phe 
Ser 
Lys 
105 
Gly 
Glu 
Phe 
Phe 
Phe 
185 
Ala 
Phe 
Val 
Leu 
Arg 
265 
Pro 
Asp 
Lys 
Phe 
Ile 
345 
Val 
Val 
Val 
Phe 
Ser 
425 
Glu 
Thr 
Ala 
Pro 
Glu 
90 
Asn 
Thr 
Arg 
Leu 
Asp 
170 
Gly 
Ala 
Thr 
Thr 
Thr 
250 
Asn 
Tyr 
Phe 
Lys 
Leu 
330 
Thr 
Ser 
Asp 
Gly 
Ser 
410 
Ser 
Ile 
Lys 
Thr 
Gly 
Asp 
Ala 
Ser 
Val 
Ala 
155 
Gln 
Gly 
Ser 
Arg 
Ser 
235 
Gly 
Lys 
Gly 
Leu 
Thr 
315 
Val 
Arg 
Glu 
Asp 
Asp 
395 
Glu 
Lys 
Glu 
Ala 
Lys 
60 
Phe 
Cys 
Thr 
Ser 
Ile 
140 
Leu 
Gln 
Asn 
Val 
Ala 
220 
Leu 
Cys 
Asp 
Thr 
Thr 
300 
Gln 
Gly 
Lys 
Phe 
380 
Tyr 
Trp 
Leu 
Phe 
Glu 
460 
45 
Tyr 
His 
Leu 
Val 
Leu 
125 
Val 
Pro 
Leu 
Pro 
Ser 
205 
Ile 
Tyr 
Ser 
Pro 
Ala 
285 
Asp 
Ile 
Gly 
Glu 
Gly 
365 
Arg 
Asn 
Gly 
Pro 
Val 
445 
Glu 
Ala 
Gly 
Tyr 
Leu 
110 
His 
Val 
Gly 
Ala 
Lys 
190 
Leu 
Leu 
Glu 
Arg 
Leu 
Met 
Leu 
Ala 
Phe 
Lys 
Pro 
Phe 
Asn 
Trp 
430 
Phe 
Ile 
Asn 
Ser 
Leu 
95 
Ile 
Val 
Ser 
Asn 
Leu 
175 
Ser 
His 
Gln 
Ala 
Glu 
255 
Glu 
Gly 
Pro 
Val 
Pro 
335 
Gln 
Glu 
Glu 
Ile 
Asn 
415 
Pro 
Gly 
Leu 
Ser 
Glu 
80 
Asn 
Trp 
Tyr 
Met 
Pro 
160 
Gln 
Val 
Leu 
Ser 
Arg 
240 
Asn 
Ile 
Val 
Asp 
Gly 
320 
Gly 
Glu 
Ser 
Asn 
Cys 
400 
Ala 
Glu 
Leu 
Ser 
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ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 1560 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 1620 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722 
<210> SEQ ID NO 4 
<211> LENGTH: 5'74 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: mutant of human BChE 
<400> SEQUENCE: 4 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
35 40 45 
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 
50 55 60 
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 
65 '70 75 80 
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 
85 90 95 
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 
100 105 110 
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 
115 120 125 
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 
130 135 140 
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 
145 150 155 160 
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 
165 170 175 
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 
180 185 190 
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 
195 200 205 
Leu Ser Pro Gly Ser His Ser Leu Phe Thr Arg Ala Ile Leu Gln Ser 
210 215 220 
Gly Ser Ala Asn Ala Pro Trp Ala Val Thr Ser Leu Tyr Glu Ala Arg 
225 230 235 240 
Asn Arg Thr Leu Asn Leu Ala Lys Leu Thr Gly Cys Ser Arg Glu Asn 
245 250 255 
Glu Thr Glu Ile Ile Lys Cys Leu Arg Asn Lys Asp Pro Gln Glu Ile 
260 265 270 
Leu Leu Asn Glu Ala Phe Val Val Pro Tyr Gly Thr Ser Leu Gly Val 
2'75 280 285 
Asn Phe Gly Pro Thr Val Asp Gly Asp Phe Leu Thr Asp Met Pro Asp 
290 295 300 
Ile Leu Leu Glu Leu Gly Gln Phe Lys Lys Thr Gln Ile Leu Val Gly 
305 310 315 320 
Val Asn Lys Asp Glu Gly Thr Trp Phe Leu Val Gly Gly Ala Pro Gly 
19 
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Phe 
Gly 
Ile 
Tyr 
385 
Pro 
Phe 
Trp 
Pro 
Arg 
465 
Asn 
Glu 
Lys 
Val 
Ala 
545 
Phe 
Ser 
Leu 
Leu 
370 
Arg 
Ala 
Phe 
Met 
Leu 
450 
Ser 
Glu 
Gln 
Leu 
Leu 
530 
Gly 
Asn 
Lys 
Lys 
355 
Phe 
Glu 
Leu 
Tyr 
Gly 
435 
Glu 
Ile 
Thr 
Lys 
Arg 
515 
Glu 
Phe 
Asp 
325 
Asp Asn 
340 
Ile Phe 
His Tyr 
Ala Leu 
Glu Phe 
405 
Tyr Phe 
420 
Val Met 
Arg Arg 
Val Lys 
Gln Asn 
485 
Tyr Leu 
500 
Ala Gln 
Met Thr 
His Arg 
Thr 
565 
Tyr 
SEQ ID NO 5 
LENGTH: 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: mutant of human BChE 
1722 
<400> SEQUENCE: 5 
gaagatgaca tcataattgc 
tttggtggca 
cttcgattca 
tatgcaaatt 
atgtggaacc 
gcacctaaac 
ggaacatcat 
gtagtgtcaa 
gaggctccag 
aatatagcag 
gcagcttcag 
attctgcaaa 
cggtaacagc 
aaaagccaca 
cttgctgtca 
caaacactga 
caaaaaatgc 
ctttacatgt 
tgaactatag 
ggaacatggg 
cctttggtgg 
ttagcctgca 
gtggttccgc 
Asn Ser Ile 
Phe Pro Gly 
360 
Thr Asp 
375 
Trp 
Gly Val 
390 
Asp 
Thr Lys Lys 
Glu His Arg 
His Gly Tyr 
440 
Asn 
455 
Asp Tyr 
Arg Ala Trp 
Asn Ser Thr 
Thr Leu Asn 
Gln Cys Arg 
520 
Asn Ile 
535 
Gly 
Trp Asn Asn 
550 
Ser Lys Lys 
aacaaagaat 
ctttcttgga 
gtctctgacc 
gaacatagat 
cctcagtgaa 
cactgtattg 
ttatgatggc 
ggtgggtgcc 
tttatttgat 
aaatcctaaa 
tttgCtttCt 
taatgctcct 
Ile 
345 
Val 
Val 
Val 
Phe 
Ser 
425 
Glu 
Thr 
Asn 
Ser 
Thr 
505 
Phe 
Asp 
Tyr 
Glu 
330 
Thr 
Ser 
Asp 
Gly 
Ser 
410 
Ser 
Ile 
Lys 
Phe 
Trp 
490 
Glu 
Trp 
Glu 
Met 
Ser 
570 
Arg 
Glu 
Asp 
Asp 
395 
Glu 
Lys 
Glu 
Ala 
Ala 
475 
Pro 
Ser 
Thr 
Ala 
Met 
555 
Cys 
ggaaaagtca 
attccctatg 
aagtggtctg 
caaagttttc 
gactgtttat 
atatggattt 
aagtttctgg 
ctaggattct 
caacagttgg 
agtgtaactc 
cctggaagcc 
tgggcggtaa 
Lys 
Phe 
380 
Tyr 
Trp 
Leu 
Phe 
Glu 
460 
Lys 
Val 
Thr 
Ser 
Glu 
540 
Asp 
Val 
Glu 
Gly 
365 
Arg 
Asn 
Gly 
Pro 
Val 
445 
Glu 
Tyr 
Phe 
Arg 
Phe 
525 
Trp 
Trp 
Gly 
Phe 
Lys 
Pro 
Phe 
Asn 
Trp 
Phe 
Ile 
Gly 
Lys 
Ile 
Phe 
Glu 
Lys 
Leu 
gagggatgaa 
cacagccacc 
atatttggaa 
caggcttcca 
atctaaatgt 
atggtggtgg 
ctcgggttga 
tagctttgcc 
ctcttcagtg 
tctttggaga 
attcattgtt 
catctcttta 
335 
Gln Glu 
Glu Ser 
Glu Asn 
Ile Cys 
400 
Asn Ala 
415 
Pro Glu 
Gly Leu 
Ser Leu 
Pro 
480 
Asn 
Ser Thr 
495 
Met Thr 
Pro Lys 
Trp Lys 
Gln 
560 
Asn 
cttgacagtt 
tcttggtaga 
tgccacaaaa 
tggatcagag 
atggattcca 
ttttcaaact 
aagagttatt 
aggaaatcct 
ggttcaaaaa 
aagttccgga 
caccagagcc 
tgaagctagg 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
21 
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aacagaacgt tgaacttagc taaattgact ggttgctcta gagagaatga gactgaaata 780 
atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 840 
ccctatggga ctcagttggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact 900 
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 960 
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 1020 
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 1080 
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140 
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 1200 
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 1260 
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320 
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 1380 
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 1440 
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 1500 
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 1560 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 1620 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722 
<210> SEQ ID NO 6 
<211> LENGTH: 5'74 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: mutant of human BChE 
<400> SEQUENCE: 6 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
20 25 30 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
35 40 45 
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 
50 55 60 
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 
65 '70 75 80 
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 
85 90 95 
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 
100 105 110 
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 
115 120 125 
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 
130 135 140 
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 
145 150 155 160 
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 
165 170 175 
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 
180 185 190 
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24 
Thr 
Leu 
Gly 
225 
Asn 
Glu 
Leu 
Ile 
305 
Val 
Phe 
Gly 
Ile 
Tyr 
385 
Pro 
Phe 
Trp 
Pro 
Arg 
465 
Asn 
Glu 
Lys 
Val 
Ala 
545 
Phe 
Leu 
Ser 
210 
Ser 
Arg 
Thr 
Leu 
Phe 
290 
Leu 
Asn 
Ser 
Leu 
Leu 
370 
Arg 
Ala 
Phe 
Met 
Leu 
450 
Ser 
Glu 
Gln 
Leu 
Leu 
530 
Gly 
Asn 
Phe 
195 
Pro 
Ala 
Thr 
Glu 
Asn 
275 
Gly 
Leu 
Lys 
Lys 
Lys 
355 
Phe 
Glu 
Leu 
Tyr 
Gly 
435 
Glu 
Ile 
Thr 
Lys 
Arg 
515 
Glu 
Phe 
Asp 
Gly 
Gly 
Asn 
Leu 
Ile 
260 
Glu 
Pro 
Glu 
Asp 
Asp 
340 
Ile 
His 
Ala 
Glu 
Tyr 
420 
Val 
Arg 
Val 
Gln 
Tyr 
500 
Ala 
Met 
His 
Tyr 
Glu 
Ser 
Ala 
Asn 
245 
Ile 
Ala 
Thr 
Leu 
Glu 
325 
Asn 
Phe 
Tyr 
Leu 
Phe 
405 
Phe 
Met 
Arg 
Lys 
Asn 
485 
Leu 
Gln 
Thr 
Arg 
Thr 
565 
SEQ ID NO 7 
LENGTH: 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: mutant of human BChE 
1722 
Ser 
His 
Pro 
230 
Leu 
Lys 
Phe 
Val 
Gly 
Gly 
Asn 
Phe 
Thr 
Gly 
390 
Thr 
Glu 
His 
Asp 
Arg 
470 
Asn 
Thr 
Gln 
Gly 
Trp 
550 
Ser 
Ser 
Ser 
215 
Trp 
Ala 
Cys 
Val 
Asp 
295 
Gln 
Thr 
Ser 
Pro 
Asp 
375 
Asp 
Lys 
His 
Gly 
Asn 
455 
Trp 
Ser 
Leu 
Cys 
Asn 
535 
Asn 
Lys 
Gly 
200 
Leu 
Ala 
Lys 
Leu 
Val 
280 
Gly 
Phe 
Trp 
Ile 
Gly 
360 
Trp 
Val 
Lys 
Arg 
Tyr 
440 
Tyr 
Ala 
Thr 
Asn 
Arg 
520 
Ile 
Asn 
Lys 
Ala 
Phe 
Val 
Leu 
Arg 
265 
Pro 
Asp 
Lys 
Phe 
Ile 
345 
Val 
Val 
Val 
Phe 
Ser 
425 
Glu 
Thr 
Asn 
Ser 
Thr 
505 
Phe 
Asp 
Tyr 
Glu 
Ala 
Thr 
Thr 
Thr 
250 
Asn 
Tyr 
Phe 
Lys 
Leu 
330 
Thr 
Ser 
Asp 
Gly 
Ser 
410 
Ser 
Ile 
Lys 
Phe 
Trp 
490 
Glu 
Trp 
Glu 
Met 
Ser 
570 
Ser 
Arg 
Ser 
235 
Gly 
Lys 
Gly 
Leu 
Thr 
315 
Val 
Arg 
Glu 
Asp 
Asp 
395 
Glu 
Lys 
Glu 
Ala 
Ala 
475 
Pro 
Ser 
Thr 
Ala 
Met 
555 
Cys 
Val 
Ala 
220 
Leu 
Cys 
Asp 
Thr 
Thr 
300 
Gln 
Gly 
Lys 
Phe 
Gln 
380 
Tyr 
Trp 
Leu 
Phe 
Glu 
460 
Lys 
Val 
Thr 
Ser 
Glu 
540 
Asp 
Val 
Ser 
205 
Ile 
Tyr 
Ser 
Pro 
285 
Asp 
Ile 
Gly 
Glu 
Gly 
365 
Arg 
Asn 
Gly 
Pro 
Val 
445 
Glu 
Tyr 
Phe 
Arg 
Phe 
525 
Trp 
Trp 
Gly 
Leu 
Leu 
Glu 
Arg 
Leu 
Met 
Leu 
Ala 
Phe 
Lys 
Pro 
Phe 
Asn 
Trp 
430 
Phe 
Ile 
Gly 
Lys 
Ile 
Phe 
Glu 
Lys 
Leu 
His 
Gln 
Ala 
Glu 
255 
Glu 
Gly 
Pro 
Val 
Pro 
335 
Gln 
Glu 
Glu 
Ile 
Asn 
415 
Pro 
Gly 
Leu 
Asn 
Ser 
495 
Met 
Pro 
Trp 
Asn 
Leu 
Ser 
Arg 
240 
Asn 
Ile 
Val 
Asp 
Gly 
320 
Gly 
Glu 
Ser 
Asn 
Cys 
400 
Ala 
Glu 
Leu 
Ser 
Pro 
480 
Thr 
Thr 
Lys 
Lys 
Gln 
560 
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Leu 
Cys 
65 
Met 
Val 
Ile 
Asp 
145 
Glu 
Trp 
Thr 
Leu 
Gly 
225 
Asn 
Glu 
Leu 
Ile 
305 
Val 
Phe 
Gly 
Ile 
Tyr 
385 
Pro 
Phe 
Trp 
Pro 
Arg 
465 
Thr 
50 
Cys 
Trp 
Trp 
Tyr 
Gly 
130 
Tyr 
Ala 
Val 
Leu 
Ser 
210 
Ser 
Arg 
Thr 
Leu 
Phe 
290 
Leu 
Asn 
Ser 
Leu 
Leu 
370 
Arg 
Ala 
Phe 
Met 
Leu 
450 
Ser 
Lys 
Gln 
Asn 
Ile 
Gly 
115 
Lys 
Arg 
Pro 
Gln 
Phe 
195 
Pro 
Pro 
Thr 
Glu 
Asn 
275 
Gly 
Leu 
Lys 
Lys 
Lys 
355 
Phe 
Glu 
Leu 
Tyr 
Gly 
435 
Glu 
Ile 
Trp 
Asn 
Pro 
Pro 
100 
Gly 
Phe 
Val 
Gly 
Lys 
180 
Gly 
Gly 
Asn 
Leu 
Ile 
260 
Glu 
Pro 
Glu 
Asp 
Asp 
340 
Ile 
His 
Ala 
Glu 
Tyr 
420 
Val 
Arg 
Val 
Ser 
Ile 
Asn 
85 
Ala 
Gly 
Leu 
Gly 
Asn 
165 
Asn 
Glu 
Ser 
Ala 
Asn 
245 
Ile 
Ala 
Thr 
Leu 
Glu 
325 
Asn 
Phe 
Tyr 
Leu 
Phe 
405 
Phe 
Met 
Arg 
Lys 
Asp 
Asp 
Thr 
Pro 
Phe 
Ala 
Ala 
150 
Met 
Ile 
Ser 
His 
Pro 
230 
Leu 
Lys 
Phe 
Val 
Gly 
310 
Gly 
Asn 
Phe 
Thr 
Gly 
390 
Thr 
Glu 
His 
Asp 
Arg 
4 '70 
Ile 
55 
Gln 
Asp 
Lys 
Gln 
Arg 
135 
Leu 
Gly 
Ala 
Ser 
Ser 
215 
Trp 
Ala 
Cys 
Val 
Asp 
295 
Gln 
Thr 
Ser 
Pro 
Asp 
375 
Asp 
Lys 
His 
Gly 
Asn 
455 
Trp 
Trp 
Ser 
Leu 
Pro 
Thr 
120 
Val 
Gly 
Leu 
Ala 
Gly 
200 
Leu 
Ala 
Lys 
Leu 
Val 
280 
Gly 
Phe 
Trp 
Ile 
Gly 
360 
Trp 
Val 
Lys 
Arg 
Tyr 
440 
Tyr 
Ala 
Asn 
Phe 
Ser 
Lys 
105 
Gly 
Glu 
Phe 
Phe 
Phe 
185 
Ala 
Phe 
Val 
Leu 
Arg 
265 
Pro 
Asp 
Lys 
Phe 
Ile 
345 
Val 
Val 
Val 
Phe 
Ser 
425 
Glu 
Thr 
Asn 
Ala 
Pro 
Glu 
90 
Asn 
Thr 
Arg 
Leu 
Asp 
170 
Gly 
Ala 
Thr 
Thr 
Thr 
250 
Asn 
Tyr 
Phe 
Lys 
Leu 
330 
Thr 
Ser 
Asp 
Gly 
Ser 
410 
Ser 
Ile 
Lys 
Phe 
Thr 
Gly 
Asp 
Ala 
Ser 
Val 
Ala 
155 
Gln 
Gly 
Ser 
Arg 
Ser 
235 
Gly 
Lys 
Gly 
Leu 
Thr 
315 
Val 
Arg 
Glu 
Asp 
Asp 
395 
Glu 
Lys 
Glu 
Ala 
Ala 
4'75 
Lys 
60 
Phe 
Cys 
Thr 
Ser 
Ile 
140 
Leu 
Gln 
Asn 
Val 
Ala 
220 
Leu 
Cys 
Asp 
Thr 
Thr 
300 
Gln 
Gly 
Lys 
Phe 
380 
Tyr 
Trp 
Leu 
Phe 
Glu 
460 
Lys 
Tyr 
His 
Leu 
Val 
Leu 
125 
Val 
Pro 
Leu 
Pro 
Ser 
205 
Ile 
Tyr 
Ser 
Pro 
Pro 
285 
Asp 
Ile 
Gly 
Glu 
Gly 
365 
Arg 
Asn 
Gly 
Pro 
Val 
445 
Glu 
Tyr 
Ala 
Gly 
Tyr 
Leu 
110 
His 
Val 
Gly 
Ala 
Lys 
190 
Leu 
Leu 
Glu 
Arg 
Leu 
Met 
Leu 
Ala 
Phe 
Lys 
Pro 
Phe 
Asn 
Trp 
Phe 
Ile 
Gly 
Asn 
Ser 
Leu 
95 
Ile 
Val 
Ser 
Asn 
Leu 
175 
Ser 
His 
Gln 
Ala 
Glu 
255 
Glu 
Gly 
Pro 
Val 
Pro 
335 
Gln 
Glu 
Glu 
Ile 
Asn 
415 
Pro 
Gly 
Leu 
Asn 
Ser 
Glu 
80 
Asn 
Trp 
Tyr 
Met 
Pro 
160 
Gln 
Val 
Leu 
Ser 
Arg 
240 
Asn 
Ile 
Val 
Asp 
Gly 
320 
Gly 
Glu 
Ser 
Asn 
Cys 
400 
Ala 
Glu 
Leu 
Ser 
Pro 
480 
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ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 
Glu 
1 
Asn 
Tyr 
Leu 
Cys 
65 
Met 
Val 
Ile 
Asp 
145 
Glu 
Trp 
Thr 
Leu 
Gly 
225 
Asn 
Glu 
Leu 
Ile 
305 
Val 
PRT 
SEQUENCE: 
Asp Asp Ile 
Leu 
Ala 
Thr 
50 
Cys 
Trp 
Trp 
Tyr 
Gly 
130 
Tyr 
Ala 
Val 
Leu 
Ser 
210 
Ser 
Arg 
Thr 
Leu 
Phe 
290 
Leu 
Asn 
Thr 
Gln 
35 
Lys 
Gln 
Asn 
Ile 
Gly 
115 
Lys 
Arg 
Pro 
Gln 
Phe 
195 
Pro 
Ala 
Thr 
Glu 
Asn 
275 
Gly 
Leu 
Lys 
Val 
Pro 
Trp 
Asn 
Pro 
Pro 
100 
Gly 
Phe 
Val 
Gly 
Lys 
180 
Gly 
Gly 
Asn 
Leu 
Ile 
260 
Glu 
Pro 
Glu 
Asp 
SEQ ID NO 10 
LENGTH: 
TYPE: 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: mutant of human BChE 
10 
Ile 
5 
Phe 
Pro 
Ser 
Ile 
Asn 
85 
Ala 
Gly 
Leu 
Gly 
Asn 
165 
Asn 
Glu 
Ser 
Ala 
Asn 
245 
Ile 
Ala 
Thr 
Leu 
Glu 
325 
Ile 
Gly 
Leu 
Asp 
Asp 
Thr 
Pro 
Phe 
Ala 
Ala 
150 
Met 
Ile 
Ser 
His 
Pro 
230 
Leu 
Lys 
Phe 
Val 
Gly 
310 
Gly 
Ala 
Gly 
Gly 
Ile 
55 
Gln 
Asp 
Lys 
Gln 
Arg 
135 
Leu 
Gly 
Ala 
Ser 
Ser 
215 
Trp 
Ala 
Cys 
Val 
Asp 
295 
Gln 
Thr 
Thr 
Thr 
Arg 
40 
Trp 
Ser 
Leu 
Pro 
Thr 
120 
Val 
Gly 
Leu 
Ala 
Gly 
200 
Leu 
Ala 
Lys 
Leu 
Val 
280 
Gly 
Phe 
Trp 
Lys 
Val 
Leu 
Asn 
Phe 
Ser 
Lys 
105 
Gly 
Glu 
Phe 
Phe 
Phe 
185 
Ala 
Phe 
Val 
Leu 
Arg 
265 
Pro 
Asp 
Lys 
Phe 
Asn 
10 
Thr 
Arg 
Ala 
Pro 
Glu 
90 
Asn 
Thr 
Arg 
Leu 
Asp 
170 
Gly 
Ala 
Thr 
Thr 
Thr 
250 
Asn 
Tyr 
Phe 
Lys 
Leu 
330 
Gly 
Ala 
Phe 
Thr 
Gly 
Asp 
Ala 
Ser 
Val 
Ala 
155 
Gln 
Gly 
Ser 
Arg 
Ser 
235 
Gly 
Lys 
Gly 
Leu 
Thr 
315 
Val 
Lys 
Phe 
Lys 
Lys 
60 
Phe 
Cys 
Thr 
Ser 
Ile 
140 
Leu 
Gln 
Asn 
Val 
Ala 
220 
Leu 
Cys 
Asp 
Thr 
Thr 
300 
Gln 
Gly 
Val 
Leu 
Lys 
45 
Tyr 
His 
Leu 
Val 
Leu 
125 
Val 
Pro 
Leu 
Pro 
Ser 
205 
Ile 
Tyr 
Ser 
Pro 
Gly 
285 
Asp 
Ile 
Gly 
Arg 
Gly 
Pro 
Ala 
Gly 
Tyr 
Leu 
110 
His 
Val 
Gly 
Ala 
Lys 
190 
Leu 
Leu 
Glu 
Arg 
Leu 
Met 
Leu 
Ala 
Gly 
15 
Ile 
Gln 
Asn 
Ser 
Leu 
95 
Ile 
Val 
Ser 
Asn 
Leu 
175 
Ser 
His 
Gln 
Ala 
Glu 
255 
Glu 
Gly 
Pro 
Val 
Pro 
335 
Met 
Pro 
Ser 
Ser 
Glu 
80 
Asn 
Trp 
Tyr 
Met 
Pro 
160 
Gln 
Val 
Leu 
Ser 
Arg 
240 
Asn 
Ile 
Val 
Asp 
Gly 
320 
Gly 
1620 
1680 
1722 
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Phe 
Gly 
Ile 
Tyr 
385 
Pro 
Phe 
Trp 
Pro 
Arg 
465 
Asn 
Glu 
Lys 
Val 
Ala 
545 
Phe 
<400> SEQUENCE: 
Ser 
Leu 
Leu 
370 
Arg 
Ala 
Phe 
Met 
Leu 
450 
Ser 
Glu 
Gln 
Leu 
Leu 
530 
Gly 
Asn 
Lys 
Lys 
355 
Phe 
Glu 
Leu 
Tyr 
Gly 
435 
Glu 
Ile 
Thr 
Lys 
Arg 
515 
Glu 
Phe 
Asp 
Asp Asn 
340 
Ile Phe 
His Tyr 
Ala Leu 
Asn 
Phe 
Thr 
Gly 
Ser Ile 
Pro Gly 
360 
Asp 
375 
Trp 
Asp Val 
390 
Glu Phe 
405 
Tyr Phe 
420 
Val Met 
Arg Arg 
Val Lys 
Thr 
Glu 
His 
Asp 
Arg 
Lys Lys 
His Arg 
Gly Tyr 
440 
Asn 
455 
Tyr 
Trp Ala 
Gln Asn 
485 
Tyr Leu 
500 
Ala Gln 
Met Thr 
His Arg 
Asn 
Thr 
Gln 
Gly 
Trp 
Ser Thr 
Leu Asn 
Cys Arg 
520 
Asn Ile 
535 
Asn Asn 
550 
Thr 
565 
Tyr 
SEQ ID NO 11 
LENGTH: 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: mutant of human BChE 
1722 
ll 
gaagatgaca tcataattgc 
tttggtggca 
cttcgattca 
tatgcaaatt 
atgtggaacc 
gcacctaaac 
ggaacatcat 
gtagtgtcaa 
gaggctccag 
aatatagcag 
gcagcttcag 
attctgcaaa 
aacagaacgt 
cggtaacagc 
aaaagccaca 
cttgctgtca 
caaacactga 
caaaaaatgc 
ctttacatgt 
tgaactatag 
ggaacatggg 
cctttggtgg 
ttagcctgca 
gtggttccgc 
tgaacttagc 
Ser Lys Lys 
aacaaagaat 
ctttcttgga 
gtctctgacc 
gaacatagat 
cctcagtgaa 
cactgtattg 
ttatgatggc 
ggtgggtgcc 
tttatttgat 
aaatcctaaa 
tttgCtttCt 
taatgctcct 
taaattgact 
Ile 
345 
Thr Arg 
Val Ser Glu 
Val Asp Asp 
Val Gly Asp 
395 
Phe Ser Glu 
410 
Ser Ser 
425 
Lys 
Glu Ile Glu 
Thr Lys Ala 
Phe Ala Asn 
Ser Trp Pro 
490 
Thr 
505 
Glu Ser 
Phe Trp Thr 
Asp Glu Ala 
Met Met 
555 
Tyr 
Glu Ser 
570 
Cys 
ggaaaagtca 
attccctatg 
aagtggtctg 
caaagttttc 
gactgtttat 
atatggattt 
aagtttctgg 
ctaggattct 
caacagttgg 
agtgtaactc 
cctggaagcc 
tgggcggtaa 
ggttgctcta 
Lys 
Phe 
380 
Tyr 
Trp 
Leu 
Phe 
Glu 
460 
Lys 
Val 
Thr 
Ser 
Glu 
540 
Asp 
Val 
Glu 
Gly 
365 
Arg 
Asn 
Gly 
Pro 
Val 
445 
Glu 
Tyr 
Phe 
Arg 
Phe 
525 
Trp 
Trp 
Gly 
Phe 
Lys 
Pro 
Phe 
Asn 
Trp 
430 
Phe 
Ile 
Gly 
Lys 
Ile 
Phe 
Glu 
Lys 
Leu 
gagggatgaa 
cacagccacc 
atatttggaa 
caggcttcca 
atctaaatgt 
atggtggtgg 
ctcgggttga 
tagctttgcc 
ctcttcagtg 
tctttggaga 
attcattgtt 
catctcttta 
gagagaatga 
Gln Glu 
Glu Ser 
Glu Asn 
Ile Cys 
400 
Asn Ala 
415 
Pro Glu 
Gly Leu 
Ser Leu 
Pro 
480 
Asn 
Ser Thr 
495 
Met Thr 
Pro Lys 
Trp Lys 
Gln 
560 
Asn 
cttgacagtt 
tcttggtaga 
tgccacaaaa 
tggatcagag 
atggattcca 
ttttcaaact 
aagagttatt 
aggaaatcct 
ggttcaaaaa 
aagttccgga 
caccagagcc 
tgaagctagg 
gactgaaata 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
35 
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atcaagtgtc ttagaaataa agatccccaa gaaattcttc tgaatgaagc atttgttgtc 840 
ccctatggga ctcctatggg tgtaaacttt ggtccgaccg tggatggtga ttttctcact 900 
gacatgccag acatattact tgaacttgga caatttaaaa aaacccagat tttggtgggt 960 
gttaataaag atgaagggac atggttttta gtcggtggtg ctcctggctt cagcaaagat 1020 
aacaatagta tcataactag aaaagaattt caggaaggtt taaaaatatt ttttccagga 1080 
gtgagtgagt ttggaaagga atccatcctt tttcattaca cagactgggt agatgatcag 1140 
agacctgaaa actaccgtga ggccttgggt gatgttgttg gggattataa tttcatatgc 1200 
cctgccttgg agttcaccaa gaagttctca gaatggggaa ataatgcctt tttctactat 1260 
tttgaacacc gatcctccaa acttccgtgg ccagaatgga tgggagtgat gcatggctat 1320 
gaaattgaat ttgtctttgg tttacctctg gaaagaagag ataattacac aaaagccgag 1380 
gaaattttga gtagatccat agtgaaacgg tgggcaaatt ttgcaaaata tgggaatcca 1440 
aatgagactc agaacaatag cacaagctgg cctgtcttca aaagcactga acaaaaatat 1500 
ctaaccttga atacagagtc aacaagaata atgacgaaac tacgtgctca acaatgtcga 1560 
ttctggacat cattttttcc aaaagtcttg gaaatgacag gaaatattga tgaagcagaa 1620 
tgggagtgga aagcaggatt ccatcgctgg aacaattaca tgatggactg gaaaaatcaa 1680 
tttaacgatt acactagcaa gaaagaaagt tgtgtgggtc tc 1722 
<210> SEQ ID NO 12 
<211> LENGTH: 5'74 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: mutant of human BChE 
<400> SEQUENCE: 12 
Glu Asp Asp Ile Ile Ile Ala Thr Lys Asn Gly Lys Val Arg Gly Met 
1 5 10 15 
Asn Leu Thr Val Phe Gly Gly Thr Val Thr Ala Phe Leu Gly Ile Pro 
20 25 30 
Tyr Ala Gln Pro Pro Leu Gly Arg Leu Arg Phe Lys Lys Pro Gln Ser 
35 40 45 
Leu Thr Lys Trp Ser Asp Ile Trp Asn Ala Thr Lys Tyr Ala Asn Ser 
50 55 60 
Cys Cys Gln Asn Ile Asp Gln Ser Phe Pro Gly Phe His Gly Ser Glu 
65 '70 75 80 
Met Trp Asn Pro Asn Thr Asp Leu Ser Glu Asp Cys Leu Tyr Leu Asn 
85 90 95 
Val Trp Ile Pro Ala Pro Lys Pro Lys Asn Ala Thr Val Leu Ile Trp 
100 105 110 
Ile Tyr Gly Gly Gly Phe Gln Thr Gly Thr Ser Ser Leu His Val Tyr 
115 120 125 
Asp Gly Lys Phe Leu Ala Arg Val Glu Arg Val Ile Val Val Ser Met 
130 135 140 
Asn Tyr Arg Val Gly Ala Leu Gly Phe Leu Ala Leu Pro Gly Asn Pro 
145 150 155 160 
Glu Ala Pro Gly Asn Met Gly Leu Phe Asp Gln Gln Leu Ala Leu Gln 
165 170 175 
Trp Val Gln Lys Asn Ile Ala Ala Phe Gly Gly Asn Pro Lys Ser Val 
180 185 190 
Thr Leu Phe Gly Glu Ser Ser Gly Ala Ala Ser Val Ser Leu His Leu 
37 
US 8,206,703 
—cont inued 
B1 
38 
Leu 
Gly 
225 
Asn 
Glu 
Leu 
Ile 
305 
Val 
Phe 
Gly 
Ile 
Tyr 
385 
Pro 
Phe 
Trp 
Pro 
Arg 
465 
Asn 
Glu 
Lys 
Val 
Ala 
545 
Phe 
Ser 
210 
Ser 
Arg 
Thr 
Leu 
Phe 
290 
Leu 
Asn 
Ser 
Leu 
Leu 
370 
Arg 
Ala 
Phe 
Met 
Leu 
450 
Ser 
Glu 
Gln 
Leu 
Leu 
530 
Gly 
Asn 
195 
Pro 
Ala 
Thr 
Glu 
Asn 
275 
Gly 
Leu 
Lys 
Lys 
Lys 
355 
Phe 
Glu 
Leu 
Tyr 
Gly 
435 
Glu 
Ile 
Thr 
Lys 
Arg 
515 
Glu 
Phe 
Asp 
Gly 
Asn 
Leu 
Ile 
260 
Glu 
Pro 
Glu 
Asp 
Asp 
340 
Ile 
His 
Ala 
Glu 
Tyr 
420 
Val 
Arg 
Val 
Gln 
Tyr 
500 
Ala 
Met 
His 
Tyr 
SEQUENCE: 
Ser 
Ala 
Asn 
245 
Ile 
Ala 
Thr 
Leu 
Glu 
325 
Asn 
Phe 
Tyr 
Leu 
Phe 
405 
Phe 
Met 
Arg 
Lys 
Asn 
485 
Leu 
Gln 
Thr 
Arg 
Thr 
565 
SEQ ID NO 13 
LENGTH: 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: mutant of human BChE 
1722 
13 
His 
Pro 
230 
Leu 
Lys 
Phe 
Val 
Gly 
Gly 
Asn 
Phe 
Thr 
Gly 
390 
Thr 
Glu 
His 
Asp 
Arg 
470 
Asn 
Thr 
Gln 
Gly 
Trp 
550 
Ser 
Ser 
215 
Trp 
Ala 
Cys 
Val 
Asp 
295 
Gln 
Thr 
Ser 
Pro 
Asp 
375 
Asp 
Lys 
His 
Gly 
Asn 
455 
Trp 
Ser 
Leu 
Cys 
Asn 
535 
Asn 
Lys 
200 
Leu 
Ala 
Lys 
Leu 
Val 
280 
Gly 
Phe 
Trp 
Ile 
Gly 
360 
Trp 
Val 
Lys 
Arg 
Tyr 
440 
Tyr 
Ala 
Thr 
Asn 
Arg 
520 
Ile 
Asn 
Lys 
Phe 
Val 
Leu 
Arg 
265 
Pro 
Asp 
Lys 
Phe 
Ile 
345 
Val 
Val 
Val 
Phe 
Ser 
425 
Glu 
Thr 
Asn 
Ser 
Thr 
505 
Phe 
Asp 
Tyr 
Glu 
Thr 
Thr 
Thr 
250 
Asn 
Tyr 
Phe 
Lys 
Leu 
330 
Thr 
Ser 
Asp 
Gly 
Ser 
410 
Ser 
Ile 
Lys 
Phe 
Trp 
490 
Glu 
Trp 
Glu 
Met 
Ser 
570 
Arg 
Ser 
235 
Gly 
Lys 
Gly 
Leu 
Thr 
315 
Val 
Arg 
Glu 
Asp 
Asp 
395 
Glu 
Lys 
Glu 
Ala 
Ala 
475 
Pro 
Ser 
Thr 
Ala 
Met 
555 
Cys 
Ala 
220 
Leu 
Cys 
Asp 
Thr 
Thr 
300 
Gln 
Gly 
Lys 
Phe 
380 
Tyr 
Trp 
Leu 
Phe 
Glu 
460 
Lys 
Val 
Thr 
Ser 
Glu 
540 
Asp 
Val 
205 
Ile 
Tyr 
Ser 
Pro 
Pro 
285 
Asp 
Ile 
Gly 
Glu 
Gly 
365 
Arg 
Asn 
Gly 
Pro 
Val 
445 
Glu 
Tyr 
Phe 
Arg 
Phe 
525 
Trp 
Trp 
Gly 
Leu 
Glu 
Arg 
Met 
Met 
Leu 
Ala 
Phe 
Lys 
Pro 
Phe 
Asn 
Trp 
Phe 
Ile 
Gly 
Lys 
Ile 
Phe 
Glu 
Lys 
Leu 
Gln 
Ala 
Glu 
255 
Glu 
Gly 
Pro 
Val 
Pro 
335 
Gln 
Glu 
Glu 
Ile 
Asn 
415 
Pro 
Gly 
Leu 
Asn 
Ser 
495 
Met 
Pro 
Trp 
Asn 
Ser 
Arg 
240 
Asn 
Ile 
Val 
Asp 
Gly 
320 
Gly 
Glu 
Ser 
Asn 
Cys 
400 
Ala 
Glu 
Leu 
Ser 
Pro 
480 
Thr 
Thr 
Lys 
Lys 
Gln 
560 
























